title: Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
abstract: OBJECTIVE
  We reported encouraging early results of allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had advanced chronic lymphocytic leukemia (CLL). Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients.
  
  
  METHODS
  Eighty-two patients, age 42 to 72 years, who had fludarabine-refractory CLL were conditioned with 2 Gy total-body irradiation alone or combined with fludarabine followed by HCT from related (n = 52) or unrelated (n = 30) donors.
  
  
  RESULTS
  Complete remission (CR) and partial remission were achieved in 55% and 15% of patients, respectively. Higher CR rates were noted after unrelated HCT (67% v 48%). The 5-year incidences of nonrelapse mortality (NRM), progression/relapse, overall survival, and progression-free survival were 23%, 38%, 50%, and 39%, respectively. Among 25 patients initially reported in CR, 8% relapsed and 8% died as a result of NRM, whereas 84% have remained alive and in CR. Among 14 responding patients who were tested and who had molecular eradication of their disease, two died as a result of NRM, two relapsed, and 10 have remained negative. At 5 years, 76% of living patients were entirely well, whereas 24% continued to receive immunosuppression for chronic graft-versus-host disease; the median performance status in each group was 100% and 90%, respectively. Lymphadenopathy > or = 5 cm, but not cytogenetic abnormalities at HCT, predicted relapse. In a risk-stratification model, patients who had lymphadenopathy less than 5 cm and no comorbidities had a 5-year OS of 71%.
  
  
  CONCLUSIONS
  Nonmyeloablative HCT resulted in a median survival of 5 years for patients who had fludarabine-refractory CLL with sustained remissions and in the continued resolution of chronic graft-versus-host disease in surviving patients.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. msorror@fhcrc.org
authors.forename: Mohamed L
authors.initials: ML
authors.lastname: Sorror
authors.forename: Barry E
authors.initials: BE
authors.lastname: Storer
authors.forename: Brenda M
authors.initials: BM
authors.lastname: Sandmaier
authors.forename: Michael
authors.initials: M
authors.lastname: Maris
authors.forename: Judith
authors.initials: J
authors.lastname: Shizuru
authors.forename: Richard
authors.initials: R
authors.lastname: Maziarz
authors.forename: Edward
authors.initials: E
authors.lastname: Agura
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Chauncey
authors.forename: Michael A
authors.initials: MA
authors.lastname: Pulsipher
authors.forename: Peter A
authors.initials: PA
authors.lastname: McSweeney
authors.forename: James C
authors.initials: JC
authors.lastname: Wade
authors.forename: Benedetto
authors.initials: B
authors.lastname: Bruno
authors.forename: Amelia
authors.initials: A
authors.lastname: Langston
authors.forename: Jerald
authors.initials: J
authors.lastname: Radich
authors.forename: Dietger
authors.initials: D
authors.lastname: Niederwieser
authors.forename: Karl G
authors.initials: KG
authors.lastname: Blume
authors.forename: Rainer
authors.initials: R
authors.lastname: Storb
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D012074:Remission Induction; D018570:Risk Assessment; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
references.citation: Leuk Lymphoma. 1995 Aug;18(5-6):493-6
references.pmid: 8528058
references.citation: Leuk Lymphoma. 1996 May;21(5-6):467-72
references.pmid: 9172812
references.citation: Biol Blood Marrow Transplant. 2007 Dec;13(12):1499-507
references.pmid: 18022580
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5788-94
references.pmid: 16043827
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2747-53
references.pmid: 12860954
references.citation: Blood. 2003 Jun 15;101(12):4944-51
references.pmid: 12595313
references.citation: Blood. 2002 Aug 15;100(4):1410-6
references.pmid: 12149225
references.citation: Blood. 2005 Oct 15;106(8):2912-9
references.pmid: 15994282
references.citation: Bone Marrow Transplant. 2002 May;29(10):817-23
references.pmid: 12058231
references.citation: J Clin Oncol. 2006 Dec 1;24(34):5343-9
references.pmid: 17088571
references.citation: Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64
references.pmid: 17084369
references.citation: Biol Blood Marrow Transplant. 2005 Oct;11(10):814-5
references.pmid: 16182182
references.citation: Cancer Res. 2003 Jan 1;63(1):36-8
references.pmid: 12517774
references.citation: Biol Blood Marrow Transplant. 2005 Jul;11(7):567-8
references.pmid: 15983557
references.citation: Cytotherapy. 2002;4(3):217-21
references.pmid: 12194718
references.citation: Leukemia. 2003 May;17(5):841-8
references.pmid: 12750695
references.citation: Leukemia. 2007 May;21(5):956-64
references.pmid: 17361231
references.citation: Blood. 2004 Oct 15;104(8):2600-2
references.pmid: 15205268
references.citation: N Engl J Med. 2000 Dec 28;343(26):1910-6
references.pmid: 11136261
references.citation: Leukemia. 2004 Oct;18(10):1637-45
references.pmid: 15343348
references.citation: Blood. 2006 Feb 15;107(4):1276-83
references.pmid: 16204307
references.citation: Blood. 2002 Feb 1;99(3):1023-9
references.pmid: 11807008
references.citation: Ann Intern Med. 1996 Feb 1;124(3):311-5
references.pmid: 8554226
references.citation: Br J Haematol. 1993 Apr;83(4):602-7
references.pmid: 8518176
references.citation: J Clin Oncol. 2007 Mar 1;25(7):799-804
references.pmid: 17283363
references.citation: Blood. 2002 May 15;99(10):3554-61
references.pmid: 11986207
references.citation: Blood. 2008 Jan 1;111(1):446-52
references.pmid: 17916744
references.citation: Leuk Lymphoma. 2002 Sep;43(9):1755-62
references.pmid: 12685828
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3819-29
references.pmid: 15809448
references.citation: J Clin Oncol. 2006 Jan 20;24(3):437-43
references.pmid: 16344317
references.citation: Blood. 2006 Jun 1;107(11):4563-9
references.pmid: 16449533
references.citation: Cancer. 2002 Apr 1;94(7):2033-9
references.pmid: 11932906
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1414-20
references.pmid: 11230486
references.citation: Leukemia. 2002 Jun;16(6):985-92
references.pmid: 12040430
references.citation: Clin Cancer Res. 2005 Nov 1;11(21):7757-63
references.pmid: 16278397
references.citation: Best Pract Res Clin Haematol. 2007 Sep;20(3):545-56
references.pmid: 17707839
references.citation: Exp Hematol. 2004 Jan;32(1):28-35
references.pmid: 14725898
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4070-8
references.pmid: 15767647
references.citation: N Engl J Med. 2003 May 1;348(18):1764-75
references.pmid: 12724482
references.citation: Hematology Am Soc Hematol Educ Program. 2004;:163-83
references.pmid: 15561682
references.citation: Blood. 2007 Jan 15;109(2):399-404
references.pmid: 17003373
references.citation: Br J Haematol. 2007 May;137(4):355-63
references.pmid: 17456058
references.citation: Blood. 1998 Jun 1;91(11):4342-9
references.pmid: 9596683
references.citation: Leukemia. 2005 Jun;19(6):1029-33
references.pmid: 15830011
references.citation: Bone Marrow Transplant. 2005 Nov;36(9):825-30
references.pmid: 16151430
references.citation: Blood. 2005 Dec 15;106(13):4389-96
references.pmid: 16131571